Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04866017 · ClinicalTrials.gov registry record · Phase 3
A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer
A Phase 3 study, sponsored by BeiGene.
- Terminated
- Registry status
- Phase 3
- Development phase
- 63
- Enrollment target
NCT04866017 is a Phase 3 study that was terminated before completion, run by BeiGene. The registered enrollment target is 63 participants.
The verdict
NCT04866017, a Phase 3 study, was terminated before completion, sponsored by BeiGene.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 63 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the safety and efficacy of ociperlimab in combination with tislelizumab compared to durvalumab in adults with stage III unresectable PD-L1-selected non-small cell lung cancer whose disease has not progressed after cCRT.
Interventions
- DRUG Tislelizumab
- RADIATION Radiotherapy
- DRUG Chemotherapy
- DRUG Durvalumab
- DRUG Ociperlimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2021-06-17 |
| Est. Completion | 2023-10-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04866017
The ClinicalTrials.gov registry entry for NCT04866017 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Tislelizumab is the first listed.
NCT04866017 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04866017 about?
NCT04866017 is a clinical study titled "A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer". The purpose of this study was to evaluate the safety and efficacy of ociperlimab in combination with tislelizumab compared to durvalumab in adults with stage III unresectable PD-L1-selected non-small cell lung cancer whose disease has not progressed after cCRT.
What is the current status of trial NCT04866017?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 63 participants. The study started on 2021-06-17. Estimated completion is 2023-10-17.
What interventions are being tested in trial NCT04866017?
The interventions under investigation include: Tislelizumab (DRUG), Radiotherapy (RADIATION), Chemotherapy (DRUG), Durvalumab (DRUG), Ociperlimab (DRUG).
Who is sponsoring clinical trial NCT04866017?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.